231 related articles for article (PubMed ID: 32132142)
21. Prevalence of Fabry's disease within hemodialysis patients in Spain.
Herrera J; Miranda CS
Clin Nephrol; 2014 Feb; 81(2):112-20. PubMed ID: 24365053
[TBL] [Abstract][Full Text] [Related]
22. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
23. [Current management of Fabry disease].
Cochat P; Liutkus A; Dubourg L; Levade T
Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
[TBL] [Abstract][Full Text] [Related]
24. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
[TBL] [Abstract][Full Text] [Related]
25. [Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease].
Thomaidis T; Relle M; Reinke J; Beck M; Schwarting A
Med Klin (Munich); 2009 Sep; 104(9):699-703. PubMed ID: 19779674
[TBL] [Abstract][Full Text] [Related]
26. Fabry disease.
Germain DP
Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
[TBL] [Abstract][Full Text] [Related]
27. A rare association between Fabry's disease and granulomatosis with polyangiitis: a potential pathogenic link.
Hanaoka H; Hashiguchi A; Konishi K; Ishii T; Kuwana M
BMC Nephrol; 2014 Oct; 15():157. PubMed ID: 25270872
[TBL] [Abstract][Full Text] [Related]
28. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
29. Anderson-Fabry disease.
Di Toro A; Favalli V; Arbustini E
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e1-e5. PubMed ID: 29538136
[No Abstract] [Full Text] [Related]
30. Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.
Lenders M; Brand E
J Med Genet; 2024 May; 61(6):531-533. PubMed ID: 38538083
[No Abstract] [Full Text] [Related]
31. Anderson-Fabry disease and the heart.
O'Mahony C; Elliott P
Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
[TBL] [Abstract][Full Text] [Related]
32. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
33. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
34. Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
Warnock DG; Wallace EL
J Med Genet; 2024 May; 61(6):534-535. PubMed ID: 38589225
[No Abstract] [Full Text] [Related]
35. Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry's disease.
Hirashio S; Taguchi T; Naito T; Maki K; Ogata S; Taniyama K; Taniguchi Y; Yorioka N
Clin Nephrol; 2009 May; 71(5):550-6. PubMed ID: 19473616
[TBL] [Abstract][Full Text] [Related]
36. [Fabry's disease revealed by stroke: a case report].
Ronzière T
Rev Med Interne; 2010 Dec; 31 Suppl 2():S260-2. PubMed ID: 21211676
[TBL] [Abstract][Full Text] [Related]
37. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.
Warnock DG; Ortiz A; Mauer M; Linthorst GE; Oliveira JP; Serra AL; Maródi L; Mignani R; Vujkovac B; Beitner-Johnson D; Lemay R; Cole JA; Svarstad E; Waldek S; Germain DP; Wanner C;
Nephrol Dial Transplant; 2012 Mar; 27(3):1042-9. PubMed ID: 21804088
[TBL] [Abstract][Full Text] [Related]
38. [Fabry's disease; towards a treatment].
Linthorst GE; Hollak CE; Bosman DK; Heymans HS; Aerts JM
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2391-5. PubMed ID: 11145093
[TBL] [Abstract][Full Text] [Related]
39. Fabry disease previously diagnosed as Henoch-Schonlein purpura.
Kim JH; Han DH; Park MY; Choi SJ; Kim JK; Hwang SD; Jin SY
Korean J Intern Med; 2015 Nov; 30(6):925-7. PubMed ID: 26552470
[No Abstract] [Full Text] [Related]
40. Fabry disease in children: agalsidase-beta enzyme replacement therapy.
Borgwardt L; Feldt-Rasmussen U; Rasmussen AK; Ballegaard M; Meldgaard Lund A
Clin Genet; 2013 May; 83(5):432-8. PubMed ID: 22880956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
